Abstract
Chinese medicine (CM) in inhalation therapy has a long history of applications since ancient China in the forms of smoke, steam vapor, medicated pillows and aromatic sachets. Over the years, thousands of clinical treatments involving the inhalation of CMs have been reported for the treatment of respiratory disease. Shuanghuanglian, Yuxingcao and Qingkailing are primarily applied in pneumonia and bronchitis. At present, metered dose inhalation (MDI), aromatic inhalation and nebulized inhalation are used extensively in practice. In particular, nebulized CM for the treatment of respiratory diseases has been applied as a noninvasive route with reduced serious adverse reactions and is equivalent to or more efficacious than its intravenous counterparts. Although nebulized CM is widely used in clinical practice, only three MDI and five aromatic inhalations of CM products have been approved by the China Food and Drug Administration (CFDA), and no products in the form of a dry powder inhaler (DPI) or in dosage forms intended for nebulization have been reported. The development of formulations for CM has focused on improving the aerodynamic performance of the particles prepared by spray drying, enhancing the bioavailability and local concentration in the respiratory tract, and increasing the mucoadhesion and sustained release of the CM upon the incorporation of novel excipients. New devices, including MDI and nebulizer devices, have been developed for the delivery of the above-mentioned particles to the pulmonary system. Although the development of CM inhalation products to meet the international quality standards is facing a number of challenges, the inhalation of CMs show great potential for further exploration, particularly as an alternative route to IV infusion for the treatment of respiratory diseases.
Keywords: Chinese medicine, inhalation, nebulizer, pulmonary disease, shuanghuanglian, yuxingcao, qingkailing.
Current Pharmaceutical Design
Title:Chinese Medicine in Inhalation Therapy: A Review of Clinical Application and Formulation Development
Volume: 21 Issue: 27
Author(s): Xiaoqing Miao, Jing Zhou, Jian Li, Yonghong Liao and Ying Zheng
Affiliation:
Keywords: Chinese medicine, inhalation, nebulizer, pulmonary disease, shuanghuanglian, yuxingcao, qingkailing.
Abstract: Chinese medicine (CM) in inhalation therapy has a long history of applications since ancient China in the forms of smoke, steam vapor, medicated pillows and aromatic sachets. Over the years, thousands of clinical treatments involving the inhalation of CMs have been reported for the treatment of respiratory disease. Shuanghuanglian, Yuxingcao and Qingkailing are primarily applied in pneumonia and bronchitis. At present, metered dose inhalation (MDI), aromatic inhalation and nebulized inhalation are used extensively in practice. In particular, nebulized CM for the treatment of respiratory diseases has been applied as a noninvasive route with reduced serious adverse reactions and is equivalent to or more efficacious than its intravenous counterparts. Although nebulized CM is widely used in clinical practice, only three MDI and five aromatic inhalations of CM products have been approved by the China Food and Drug Administration (CFDA), and no products in the form of a dry powder inhaler (DPI) or in dosage forms intended for nebulization have been reported. The development of formulations for CM has focused on improving the aerodynamic performance of the particles prepared by spray drying, enhancing the bioavailability and local concentration in the respiratory tract, and increasing the mucoadhesion and sustained release of the CM upon the incorporation of novel excipients. New devices, including MDI and nebulizer devices, have been developed for the delivery of the above-mentioned particles to the pulmonary system. Although the development of CM inhalation products to meet the international quality standards is facing a number of challenges, the inhalation of CMs show great potential for further exploration, particularly as an alternative route to IV infusion for the treatment of respiratory diseases.
Export Options
About this article
Cite this article as:
Miao Xiaoqing, Zhou Jing, Li Jian, Liao Yonghong and Zheng Ying, Chinese Medicine in Inhalation Therapy: A Review of Clinical Application and Formulation Development, Current Pharmaceutical Design 2015; 21 (27) . https://dx.doi.org/10.2174/1381612821666150820110550
DOI https://dx.doi.org/10.2174/1381612821666150820110550 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antioxidant Therapy for Prevention of Inflammation, Ischemic Reperfusion Injuries and Allograft Rejection
Cardiovascular & Hematological Agents in Medicinal Chemistry Blood Biomarkers in Cardioembolic Stroke
Current Cardiology Reviews GPER and ER: Estrogen Receptors with Distinct Biological Roles in Breast Cancer
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Pharmacological and Biological Activities of Xanthones
Anti-Infective Agents in Medicinal Chemistry EDITORIAL [Hot Topic-II: PPAR Ligands and Cardiovascular Disorders: Friend or Foe (Guest Editors: Pitchai Balakumar and Gowraganahalli Jagadeesh)]
Current Molecular Pharmacology Peroxisome Proliferator-Activated Receptor γ Agonists as Insulin Sensitizers: From the Discovery to Recent Progress
Current Topics in Medicinal Chemistry Predictors of Left Ventricular Ejection Fraction Improvement after Radiofrequency Catheter Ablation in Patients with PVC-Induced Cardiomyopathy: A Systematic Review
Current Cardiology Reviews Pulmonary Rehabilitation as Evaluated by Clinical Trials: An Overview
Reviews on Recent Clinical Trials LncRNA as a Therapeutic Target for Angiogenesis
Current Topics in Medicinal Chemistry Remodeling of the Myocardium and Potential Targets in the Collagen Degradation and Synthesis Pathways
Current Drug Targets - Cardiovascular & Hematological Disorders Molecular Effects Elicited In Vitro by Red Wine on Human Healthy Peripheral Blood Mononuclear Cells: Potential Therapeutical Application of Polyphenols to Diet-Related Chronic Diseases
Current Pharmaceutical Design Management of Chemotherapy Induced Cardiomyopathy
Current Cardiology Reviews Arterial Hypertension and Kidney Circulation
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Nutrigenomics and Personalized Diet: What are the Anticipated Impacts for Research on Chronic Diseases and Public Health?
Current Pharmacogenomics and Personalized Medicine Adult Stem Cell Therapy for Cardiac Repair in Patients After Acute Myocardial Infarction Leading to Ischemic Heart Failure: An Overview of Evidence from the Recent Clinical Trials
Current Cardiology Reviews Genomic Variations Affecting Biological Effects of Statins
Current Drug Metabolism Natalizumab Modifies Catecholamines Levels Present in Patients with Relapsing- Remitting Multiple Sclerosis
Current Pharmaceutical Design Update on Glycoprotein IIb/IIIa: Role in Primary Coronary Intervention
Cardiovascular & Hematological Agents in Medicinal Chemistry Patent Selections
Recent Patents on Cardiovascular Drug Discovery Thromboxane Synthase Inhibitors and Thromboxane A2 Receptor Antagonists: A Quantitative Structure Activity Relationships (QSARs) Analysis
Current Medicinal Chemistry